World Investment Advisors Purchases 19,623 Shares of CVS Health Corporation $CVS

World Investment Advisors increased its holdings in CVS Health Corporation (NYSE:CVS) by 36.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 73,409 shares of the pharmacy operator’s stock after acquiring an additional 19,623 shares during the quarter. World Investment Advisors’ holdings in CVS Health were worth $5,826,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in CVS. Investors Asset Management of Georgia Inc. GA ADV raised its holdings in shares of CVS Health by 3.1% in the 4th quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 10,150 shares of the pharmacy operator’s stock valued at $806,000 after purchasing an additional 303 shares in the last quarter. ELCO Management Co. LLC bought a new stake in shares of CVS Health in the 4th quarter valued at about $200,000. Meridian Wealth Management LLC raised its holdings in shares of CVS Health by 2.0% in the 4th quarter. Meridian Wealth Management LLC now owns 9,605 shares of the pharmacy operator’s stock valued at $762,000 after purchasing an additional 190 shares in the last quarter. HighPoint Advisor Group LLC raised its holdings in shares of CVS Health by 0.5% in the 4th quarter. HighPoint Advisor Group LLC now owns 49,169 shares of the pharmacy operator’s stock valued at $3,902,000 after purchasing an additional 240 shares in the last quarter. Finally, Versor Investments LP raised its holdings in shares of CVS Health by 5.7% in the 4th quarter. Versor Investments LP now owns 38,777 shares of the pharmacy operator’s stock valued at $3,077,000 after purchasing an additional 2,082 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Stock Up 3.1%

NYSE:CVS opened at $98.14 on Thursday. The company has a market cap of $125.22 billion, a PE ratio of 43.24, a P/E/G ratio of 0.93 and a beta of 0.60. CVS Health Corporation has a twelve month low of $58.35 and a twelve month high of $98.22. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The company’s 50 day moving average is $78.07 and its two-hundred day moving average is $78.36.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.36. The company had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. CVS Health’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Analysts anticipate that CVS Health Corporation will post 7.46 EPS for the current year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd were issued a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend was Thursday, April 23rd. CVS Health’s dividend payout ratio is 117.18%.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: JPMorgan raised its price target on CVS Health to $111 from $101 and kept an overweight rating, while Sanford C. Bernstein lifted its target to $106 from $94 and maintained outperform, signaling continued analyst confidence. Article Title
• Positive Sentiment: CVS Health has been highlighted for strong Q1 results and improving profitability, with recent coverage noting the stock reached a new 52-week high after beating earnings and revenue expectations. Article Title
• Positive Sentiment: Analysts and market commentary are also pointing to CVS as a top-ranked growth/dividend name, which may be helping sentiment around the stock. Article Title
• Neutral Sentiment: CVS’s Omnicare subsidiary won bankruptcy court approval to sell its business to GenieRx, a step that should help CVS continue reshaping that unit, though it is more of a restructuring story than a direct earnings driver. Article Title
• Neutral Sentiment: CVS also announced AI and MinuteClinic-related initiatives, including recognition for enterprise AI and a weight-loss program update, which support the company’s innovation narrative but are not likely immediate stock catalysts. Article Title
• Negative Sentiment: There were no major fresh negative headlines in the latest batch; however, investors may still be watching execution risk around restructuring, formulary changes, and broader healthcare margin pressures.

Insider Activity at CVS Health

In other news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the sale, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. This represents a 87.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.85% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. DA Davidson boosted their price target on shares of CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Wolfe Research reduced their price target on shares of CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a report on Monday, March 2nd. Robert W. Baird boosted their price target on shares of CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a report on Wednesday, April 15th. Sanford C. Bernstein lifted their price objective on shares of CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Wall Street Zen raised shares of CVS Health from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Twenty-two analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, CVS Health currently has an average rating of “Moderate Buy” and an average price target of $97.00.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.